• Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
Monday, January 30, 2023
Massachusetts Digital News
  • Home
  • US
  • Business
  • World
  • Boston
  • Worcester
  • Springfield
  • Cambridge
  • Lowell
  • Brockton
  • Press Releases
  • Videos
No Result
View All Result
  • Home
  • US
  • Business
  • World
  • Boston
  • Worcester
  • Springfield
  • Cambridge
  • Lowell
  • Brockton
  • Press Releases
  • Videos
No Result
View All Result
No Result
View All Result
Home Cambridge

Sarepta Therapeutics (SRPT) Scheduled To Post Quarterly Earnings On Tuesday

by NewsReporter
February 23, 2022
in Cambridge
sarepta-therapeutics-(srpt)-scheduled-to-post-quarterly-earnings-on-tuesday
Share on FacebookShare on Twitter

Sarepta Therapeutics logoSarepta Therapeutics (NASDAQ:SRPT) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, March 1st. Analysts expect the company to announce earnings of ($1.21) per share for the quarter.

SRPT stock opened at $75.04 on Wednesday. Sarepta Therapeutics has a 12 month low of $61.31 and a 12 month high of $101.24. The company’s 50 day simple moving average is $78.73 and its 200-day simple moving average is $81.64. The company has a debt-to-equity ratio of 2.33, a current ratio of 5.85 and a quick ratio of 5.08. The firm has a market capitalization of $6.53 billion, a PE ratio of -12.26 and a beta of 1.26.

Several institutional investors have recently added to or reduced their stakes in SRPT. Benchmark Investment Advisors LLC bought a new stake in Sarepta Therapeutics during the fourth quarter valued at $360,000. Metropolitan Life Insurance Co NY grew its position in shares of Sarepta Therapeutics by 8.3% in the 4th quarter. Metropolitan Life Insurance Co NY now owns 5,541 shares of the biotechnology company’s stock worth $499,000 after buying an additional 425 shares during the period. Bank Julius Baer & Co. Ltd Zurich grew its position in Sarepta Therapeutics by 221.2% during the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 11,037 shares of the biotechnology company’s stock valued at $994,000 after purchasing an additional 7,601 shares during the last quarter. Amalgamated Bank lifted its holdings in shares of Sarepta Therapeutics by 25.8% during the fourth quarter. Amalgamated Bank now owns 17,382 shares of the biotechnology company’s stock valued at $1,565,000 after purchasing an additional 3,564 shares in the last quarter. Finally, Advisors Asset Management Inc. lifted its position in Sarepta Therapeutics by 1.0% during the fourth quarter. Advisors Asset Management Inc. now owns 23,780 shares of the biotechnology company’s stock valued at $2,141,000 after purchasing an additional 229 shares during the period. 73.83% of the stock is owned by hedge funds and other institutional investors.

(Ad)

Right now helium is one of world’s best investments. It’s Earth’s most nonrenewable resource and it’s fast running out. That’s a crisis because helium is critical in medical diagnostics, military weapons, and semiconductors, which are the chips that run all the 21st century’s gadgets, appliances, and vehicles.

Several research analysts recently commented on the stock. Royal Bank of Canada cut their price target on shares of Sarepta Therapeutics from $148.00 to $145.00 and set an “outperform” rating on the stock in a report on Thursday, November 4th. Morgan Stanley lowered their target price on Sarepta Therapeutics from $92.00 to $71.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 1st. Cantor Fitzgerald raised their price objective on Sarepta Therapeutics from $128.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, November 4th. JPMorgan Chase & Co. raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the company from $88.00 to $130.00 in a research report on Friday, November 5th. Finally, Oppenheimer raised shares of Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $125.00 price target for the company in a research report on Thursday, December 9th. Five investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $120.43.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Recommended Stories

  • Get a free copy of the StockNews.com research report on Sarepta Therapeutics (SRPT)
  • 3 More Tech Stocks to Target During Market Weakness
  • Hit the Buy Button on These 3 Oversold Tech Stocks
  • It’s Time To Shut The Door On Masonite International 
  • Pfizer Stock is Ready to be Added to Your Portfolio
  • The Purely Technical Reason Oil Will Hit $122 

Earnings History for Sarepta Therapeutics (NASDAQ:SRPT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Sarepta Therapeutics right now?

Before you consider Sarepta Therapeutics, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Sarepta Therapeutics wasn’t on the list.

While Sarepta Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here


Read More Here

Related Posts

head-to-head-survey:-voyager-therapeutics-(nasdaq:vygr)-&-surface-oncology-(nasdaq:surf)

Head-To-Head Survey: Voyager Therapeutics (NASDAQ:VYGR) & Surface Oncology (NASDAQ:SURF)

by Duong
April 14, 2022
0

Posted by admin on Apr 14th, 2022 Voyager Therapeutics (NASDAQ:VYGR – Get Rating) and Surface Oncology (NASDAQ:SURF – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk...

energy-workshop-–-announcements-–-e-flux

Energy Workshop – Announcements – E-Flux

by Duong
April 13, 2022
0

The first edition of the Norman Foster Foundation’s Energy Workshop will take place from April 25–29, 2022 with the support of GS Energy. “With energy, we stand on the shoulders of giants with our heads in the clouds,” states the workshop’s Mentor, Luke Olsen. As he puts it, “we need to...

men’s-and-women’s-tennis-complete-successful-weekend-with-wins-over-columbia,-cornell-|-sports-|-the-harvard-crimson

Men’s And Women’s Tennis Complete Successful Weekend With Wins Over Columbia, Cornell | Sports | The Harvard Crimson

by NewsReporter
April 12, 2022
0

“One thing that our team has really come a long way in this semester is with our confidence and belief in ourselves,” said first-year Holly Fischer. “So I think that even though we were down, everyone who was playing was fighting so hard and really leaving everything out on the...

artist-pritika-chowdhry’s-‘anti-memorials’-illustrate-what-is-excluded-from-collective-memories-of-partition

Artist Pritika Chowdhry’s ‘anti-Memorials’ Illustrate What Is Excluded From Collective Memories Of Partition

by Duong
April 11, 2022
0

The Jallianwala Bagh Massacre is one of the most significant events in the history of the sub-continent. Many people, including women and children, lost their lives on April 13, 1919, the day of Baisakhi when General Reginald Edward Dy ordered soldiers to open fire on the gathering — camping in...

Massachusetts Digital News

© 2021 Massachusetts Digital News

Navigate Site

  • Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer

Follow Us

No Result
View All Result
  • Home
  • DMCA Policy
  • Medical Disclaimer
  • Privacy Policy
  • Disclosure
  • CCPA
  • Terms of Use

© 2021 Massachusetts Digital News

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT